Abstract
In recent years a significant progress has been made in the field of molecular background of vestibular schwannoma (VS) emergence and growth. Main genetic and epigenetic aberrations, as well as gene expression changes and specific signaling pathways have been described, that contribute to the development of sporadic VS, and these connected with type II neurofibromatosis (NF2). These findings led to search for potential prognostic markers and biological treatment. In this article we summarize main research directions in the field of molecular diagnostics and biological therapies for VS.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
